Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0
|
作者：
Bose, Subhadeep [1 ]
Khaja, Mujtaba Syed [1 ]
Siva, Asha [1 ]
Wilson, Paula [1 ]
Grist, Helen [1 ]
Murukesh, Nishanth [1 ]
机构：
[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21091
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [32] Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
    Attili, I.
    Valenza, C.
    Santoro, C.
    Antonarelli, G.
    Aliaga, P. Trillo
    Del Signore, E.
    Catania, C.
    Spitaleri, G.
    Passaro, A.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S51 - S51
  • [33] PERLA: Randomized Phase II Trial of Dostarlimab plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic Non-Squamous NSCLC
    Spira, A.
    Lim, S. M.
    Griesinger, F.
    De Marinis, F.
    Mccarthy, T.
    Huseinovic, N.
    O'Donnell, S.
    Ahn, J. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1013 - S1014
  • [34] Audit of safety and tolerability of combination platinum-pemetrexed-pembrolizumab in advanced non-squamous NSCLC in the real-world setting of a UK Cancer Centre
    Bhalla, N.
    Ghoz, H.
    LUNG CANCER, 2020, 139 : S53 - S54
  • [35] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [36] Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China
    Jiang, Yuan
    Wang, Xingwei
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (03) : 139 - 144
  • [37] Real-world Outcomes of Advanced Head and Neck Squamous Cell Carcinoma in Patients Receiving Pembrolizumab: An Australian Single-Centre Experience
    Leslie, Claudia
    Boyer, Michael
    Lee, Jenny H.
    Kao, Steven
    Hui, Mun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 48 - 49
  • [38] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
  • [39] Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
    Ikeuchi, Nobumitsu
    Igata, Fumiyasu
    Kinoshita, Eriko
    Kawabata, Toshiaki
    Tan, Ibun
    Osaki, Yusuke
    Otsuka, Rikako
    On, Rintaro
    Ikeda, Takato
    Nakao, Akira
    Sasaki, Tomoya
    Aoyama, Takashi
    Hirano, Ryosuke
    Harada, Taishi
    Ebi, Noriyuki
    Fujita, Masaki
    Inoue, Hiroyuki
    ANTICANCER RESEARCH, 2023, 43 (02) : 713 - 724
  • [40] A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
    Fujimoto, Daichi
    Miura, Satoru
    Yoshimura, Kenichi
    Wakuda, Kazushige
    Oya, Yuko
    Haratani, Koji
    Itoh, Shoichi
    Uemura, Takehiro
    Morinaga, Ryotaro
    Takahama, Takayuki
    Nakashima, Kazuhisa
    Tachihara, Motoko
    Saito, Go
    Tanizaki, Junko
    Otsubo, Kohei
    Ikeda, Satoshi
    Matsumoto, Hirotaka
    Hara, Satoshi
    Hata, Akito
    Masuda, Takeshi
    Yamamoto, Nobuyuki
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
12345